ProSomnus Secures $38 Million Strategic Investment from Catalio Capital Management to Scale Smart Sleep Medicine™
SAN FRANCISCO--(BUSINESS WIRE)--Feb 18, 2026-- ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy ® and pioneer in Smart Sleep Medicine™, today announced a strategic investment from Catalio Capital …